Retrospective 237 low-risk healthcare workers in Turkey, 123 treated with favipiravir and 114 treated with HCQ, showing lower hospitalization and faster viral clearance with favipiravir, and similar improvement. This study is subject to substantial
confounding by time because the patients in each group are from different time periods with an overall period of 10 months including the beginning of the pandemic, resulting in significant differences in variants encountered and SOC. Propensity for hospital admission may also have changed significantly.
risk of hospitalization, 79.4% lower, RR 0.21, p = 0.001, treatment 4 of 123 (3.3%), control 18 of 114 (15.8%), NNT 8.0.
|
recovery time, 11.0% higher, relative time 1.11, p = 0.51, treatment 123, control 114.
|
time to viral-, 21.6% lower, relative time 0.78, p < 0.001, treatment 123, control 114.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
This study is excluded in meta
analysis:
substantial
confounding by time likely due to separation of groups in different time periods over an extended period of time.
Turan et al., 2/1/2022, retrospective, Turkey, Europe, peer-reviewed, mean age 33.4, 10 authors, study period 11 March, 2020 - 1 January, 2021, this trial compares with another treatment - results may be better when compared to placebo.